<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>1133</ReferenceId>
        <DateLastUpdated>2020-09-30-07:00</DateLastUpdated>
        <Article>
            <PubmedId>15919893</PubmedId>
            <Abstract>Conventional influenza vaccines can prevent infection, but their efficacy depends on the degree of antigenic "match" between the strains used for vaccine preparation and those circulating in the population. A universal influenza vaccine based on invariant regions of the virus, able to provide broadly cross-reactive protection, without requiring continuous manufacturing update, would solve a major medical need. Since the temporal and geographical dominance of the influenza virus type and/or subtype (A/H3, A/H1, or B) cannot yet be predicted, a universal vaccine, like the vaccines currently in use, should include both type A and type B influenza virus components. However, while encouraging preclinical data are available for influenza A virus, no candidate universal vaccine is available for influenza B virus. We show here that a peptide conjugate vaccine, based on the highly conserved maturational cleavage site of the HA(0) precursor of the influenza B virus hemagglutinin, can elicit a protective immune response against lethal challenge with viruses belonging to either one of the representative, non-antigenically cross-reactive influenza B virus lineages. We demonstrate that protection by the HA(0) vaccine is mediated by antibodies, probably through effector mechanisms, and that a major part of the protective response targets the most conserved region of HA(0), the P1 residue of the scissile bond and the fusion peptide domain. In addition, we present preliminary evidence that the approach can be extended to influenza A virus, although the equivalent HA(0) conjugate is not as efficacious as for influenza B virus.</Abstract>
            <ArticleYear>2005</ArticleYear>
            <ArticlePages>7380-8</ArticlePages>
            <ArticleTitle>Universal influenza B vaccine based on the maturational cleavage site of the hemagglutinin precursor.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Bianchi</LastName>
                    <ForeName>Elisabetta</ForeName>
                </Author>
                <Author>
                    <LastName>Liang</LastName>
                    <ForeName>Xiaoping</ForeName>
                </Author>
                <Author>
                    <LastName>Ingallinella</LastName>
                    <ForeName>Paolo</ForeName>
                </Author>
                <Author>
                    <LastName>Finotto</LastName>
                    <ForeName>Marco</ForeName>
                </Author>
                <Author>
                    <LastName>Chastain</LastName>
                    <ForeName>Michael A</ForeName>
                </Author>
                <Author>
                    <LastName>Fan</LastName>
                    <ForeName>Jiang</ForeName>
                </Author>
                <Author>
                    <LastName>Fu</LastName>
                    <ForeName>Tong-Ming</ForeName>
                </Author>
                <Author>
                    <LastName>Song</LastName>
                    <ForeName>Hong Chang</ForeName>
                </Author>
                <Author>
                    <LastName>Horton</LastName>
                    <ForeName>Melanie S</ForeName>
                </Author>
                <Author>
                    <LastName>Freed</LastName>
                    <ForeName>Daniel C</ForeName>
                </Author>
                <Author>
                    <LastName>Manger</LastName>
                    <ForeName>Walter</ForeName>
                </Author>
                <Author>
                    <LastName>Wen</LastName>
                    <ForeName>Emily</ForeName>
                </Author>
                <Author>
                    <LastName>Shi</LastName>
                    <ForeName>Li</ForeName>
                </Author>
                <Author>
                    <LastName>Ionescu</LastName>
                    <ForeName>Roxana</ForeName>
                </Author>
                <Author>
                    <LastName>Price</LastName>
                    <ForeName>Colleen</ForeName>
                </Author>
                <Author>
                    <LastName>Wenger</LastName>
                    <ForeName>Marc</ForeName>
                </Author>
                <Author>
                    <LastName>Emini</LastName>
                    <ForeName>Emilio A</ForeName>
                </Author>
                <Author>
                    <LastName>Cortese</LastName>
                    <ForeName>Riccardo</ForeName>
                </Author>
                <Author>
                    <LastName>Ciliberto</LastName>
                    <ForeName>Gennaro</ForeName>
                </Author>
                <Author>
                    <LastName>Shiver</LastName>
                    <ForeName>John W</ForeName>
                </Author>
                <Author>
                    <LastName>Pessi</LastName>
                    <ForeName>Antonello</ForeName>
                </Author>
            </Authors>
            <Affiliations>Department of Molecular &amp; Cell Biology, IRBM P. Angeletti, Via Pontina Km 30.600, 00040 Pomezia (Rome) Italy.</Affiliations>
            <ArticleChemicalList>Antibodies, Viral;Hemagglutinin Glycoproteins, Influenza Virus;Influenza Vaccines;Peptides;Protein Precursors;Vaccines, Conjugate</ArticleChemicalList>
            <ArticleMeshHeadingsList>Amino Acid Sequence; Animals; Antibodies, Viral(blood); Drug Design; Hemagglutinin Glycoproteins, Influenza Virus(chemistry; genetics; metabolism); Humans; Influenza A virus(immunology); Influenza B virus(immunology; pathogenicity); Influenza Vaccines(administration &amp; dosage; chemistry; immunology); Influenza, Human(prevention &amp; control); Mice; Mice, Inbred BALB C; Models, Molecular; Molecular Sequence Data; Peptides(chemistry; genetics; immunology); Protein Precursors(chemistry; genetics; metabolism); Vaccines, Conjugate(administration &amp; dosage; chemistry; immunology)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>79</Volume>
                <Issue>12</Issue>
                <Title>Journal of virology</Title>
                <Issn>1098-5514</Issn>
                <MedlineTa>J Virol</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>B/HA0</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>PAKLLKERGFFGAIAGFLE</LinearSequence>
                        <StartingPosition>345</StartingPosition>
                        <EndingPosition>363</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P03462.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>11520</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table 1</LocationOfData>
                <EpitopeId>46841</EpitopeId>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 2 and text page 7381</LocationOfData>
                        <BCellId>1864306</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10090</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Unknown</InVivoProcessType>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The details of the immunization procedure were not described.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>310</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <QuantitativeMeasurement>52.5</QuantitativeMeasurement>
                            <MeasurementInequality>=</MeasurementInequality>
                            <AssayComments>Residues Arg8, Phe11, and Phe17 were critical residues for the epitope binding to the mAb using a panel of alanine scanning mutants of the epitope as measured by a competitive fluorescence polarization immunoassay.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Ascitic Fluid</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>O8F12</AssayedAntibodyName>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>PAKLLKERGFFGAIAGFLE</LinearSequence>
                                        <StartingPosition>345</StartingPosition>
                                        <EndingPosition>363</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P03462.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11520</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1864213</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo to prevent or reduce disease</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>PAKLLKERGFFGAIAGFLE</LinearSequence>
                                            <StartingPosition>345</StartingPosition>
                                            <EndingPosition>363</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P03462.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>11520</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ComplexedMolecule>
                                        <ComplexType>Protein conjugate</ComplexType>
                                        <PeptideModifications/>
                                        <SourceMolecule>
                                            <GenBankId>AAA25457.1</GenBankId>
                                        </SourceMolecule>
                                        <MoleculeSourceOrganismId>487</MoleculeSourceOrganismId>
                                    </ComplexedMolecule>
                                </ImmunogenContainingObject>
                                <Adjuvant>Alum (Aluminum hydroxide gel)</Adjuvant>
                                <Adjuvant>QS21</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>2 doses, administered at intervals of 4 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>124</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Mice immunized with B/HA0 vaccine were protected from infection with Influenza B virus (B/Hong Kong/330/2001) with 100% survival.</AssayComments>
                        </AssayInformation>
                        <Antigen>
                            <AntigenReferenceName>Influenza B virus (B/Hong Kong/330/2001)</AntigenReferenceName>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Taxonomic Child</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>206203</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1864214</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo to prevent or reduce disease</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>PAKLLKERGFFGAIAGFLE</LinearSequence>
                                            <StartingPosition>345</StartingPosition>
                                            <EndingPosition>363</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P03462.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>11520</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ComplexedMolecule>
                                        <ComplexType>Protein conjugate</ComplexType>
                                        <PeptideModifications/>
                                        <SourceMolecule>
                                            <GenBankId>AAA25457.1</GenBankId>
                                        </SourceMolecule>
                                        <MoleculeSourceOrganismId>487</MoleculeSourceOrganismId>
                                    </ComplexedMolecule>
                                </ImmunogenContainingObject>
                                <Adjuvant>Alum (Aluminum hydroxide gel)</Adjuvant>
                                <Adjuvant>QS21</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>2 doses, administered at intervals of 4 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>124</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Mice immunized with B/HA0 vaccine were protected from infection with Influenza B virus (B/Yamanashi/166/98) with 100% survival.</AssayComments>
                        </AssayInformation>
                        <Antigen>
                            <AntigenReferenceName>Influenza B virus (B/Yamanashi/166/98)</AntigenReferenceName>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Taxonomic Child</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>416659</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>15929</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>PAKLLKERGFFGAIAGFLE</LinearSequence>
                                            <StartingPosition>345</StartingPosition>
                                            <EndingPosition>363</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P03462.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>11520</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ComplexedMolecule>
                                        <ComplexType>Protein conjugate</ComplexType>
                                        <PeptideModifications/>
                                        <SourceMolecule>
                                            <GenBankId>AAA25457.1</GenBankId>
                                        </SourceMolecule>
                                        <MoleculeSourceOrganismId>487</MoleculeSourceOrganismId>
                                    </ComplexedMolecule>
                                </ImmunogenContainingObject>
                                <Adjuvant>Alum (Aluminum hydroxide gel)</Adjuvant>
                                <Adjuvant>QS21</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>2 doses, administered at intervals of 4 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Serum from the epitope conjugate immunized mice recognized the epitope by ELISA in an dose-dependent manner.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>Serum</AssayedAntibodyName>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>PAKLLKERGFFGAIAGFLE</LinearSequence>
                                        <StartingPosition>345</StartingPosition>
                                        <EndingPosition>363</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P03462.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11520</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>15953</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>PAKLLKERGFFGAIAGFLE</LinearSequence>
                                            <StartingPosition>345</StartingPosition>
                                            <EndingPosition>363</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P03462.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>11520</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ComplexedMolecule>
                                        <ComplexType>Protein conjugate</ComplexType>
                                        <PeptideModifications/>
                                        <SourceMolecule>
                                            <GenBankId>AAA25457.1</GenBankId>
                                        </SourceMolecule>
                                        <MoleculeSourceOrganismId>487</MoleculeSourceOrganismId>
                                    </ComplexedMolecule>
                                </ImmunogenContainingObject>
                                <Adjuvant>Alum (Aluminum hydroxide gel)</Adjuvant>
                                <Adjuvant>QS21</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>2 doses, administered at intervals of 4 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AdoptiveTransfer>
                            <RecipientOrganism>
                                <OrganismId>10000000</OrganismId>
                            </RecipientOrganism>
                            <TransferredAntibodyMolecule>
                                <TransferredAntibodyMoleculeSourceMaterial>Serum</TransferredAntibodyMoleculeSourceMaterial>
                                <TransferredAntibodyMoleculeImmunoglobulinDomain>Entire Antibody</TransferredAntibodyMoleculeImmunoglobulinDomain>
                                <TransferredAntibodyMoleculePurificationStatus>Polyclonal</TransferredAntibodyMoleculePurificationStatus>
                            </TransferredAntibodyMolecule>
                            <AdoptiveTransferComments>FcR(-) and FcR(+) BALB/c mice were used as recipient mice.</AdoptiveTransferComments>
                        </AdoptiveTransfer>
                        <AssayInformation>
                            <AssayTypeId>602</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Adoptive transfer of serum from B-HA0 vaccine immunized mice protected recipient mice from infection with Influenza B virus/Ann Arbor/4/55 with 90% survival, compared to 10% in the control group. This protection depended on the FcgammaR effector pathway.</AssayComments>
                        </AssayInformation>
                        <Antigen>
                            <AntigenReferenceName>Influenza B virus/Ann Arbor/4/55</AntigenReferenceName>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Taxonomic Child</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>10001880</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figures 3 and 7</LocationOfData>
                        <BCellId>15945</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo to prevent or reduce disease</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>PAKLLKERGFFGAIAGFLE</LinearSequence>
                                            <StartingPosition>345</StartingPosition>
                                            <EndingPosition>363</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P03462.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>11520</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ComplexedMolecule>
                                        <ComplexType>Protein conjugate</ComplexType>
                                        <PeptideModifications/>
                                        <SourceMolecule>
                                            <GenBankId>AAA25457.1</GenBankId>
                                        </SourceMolecule>
                                        <MoleculeSourceOrganismId>487</MoleculeSourceOrganismId>
                                    </ComplexedMolecule>
                                </ImmunogenContainingObject>
                                <Adjuvant>Alum (Aluminum hydroxide gel)</Adjuvant>
                                <Adjuvant>QS21</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>2 doses, administered at intervals of 4 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>125</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Mice immunized with the epitope (B/HA0) vaccine were protected from infection with influenza B/Ann Arbor/4/55 with 100% of survival, compared to only 10% of the control group survived. Mice receiving the B/HA0 vaccine had only 10% maximum weight loss, compared to the 30% weight loss in control mice. The B/HA0 vaccine also reduced viral replication in the vaccinated mice's lungs.</AssayComments>
                        </AssayInformation>
                        <Antigen>
                            <AntigenReferenceName>Influenza B virus/Ann Arbor/4/55</AntigenReferenceName>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Taxonomic Child</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>10001880</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 2 and text page 7381</LocationOfData>
                        <BCellId>1864305</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10090</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Unknown</InVivoProcessType>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The details of the immunization procedure were not described.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>310</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <QuantitativeMeasurement>86.2</QuantitativeMeasurement>
                            <MeasurementInequality>=</MeasurementInequality>
                            <AssayComments>Residues Arg8, Phe11, and Phe17 were critical residues for the epitope binding to the mAb using a panel of alanine scanning mutants of the epitope as measured by a competitive fluorescence polarization immunoassay.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Ascitic Fluid</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>mAb D9E</AssayedAntibodyName>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>PAKLLKERGFFGAIAGFLE</LinearSequence>
                                        <StartingPosition>345</StartingPosition>
                                        <EndingPosition>363</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P03462.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11520</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>A/H3/HA0</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>NVPEKQTRGIFGAIAGFIE</LinearSequence>
                        <StartingPosition>322</StartingPosition>
                        <EndingPosition>340</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P12589.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>119210</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table 1</LocationOfData>
                <EpitopeId>46444</EpitopeId>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 6</LocationOfData>
                        <BCellId>1864299</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo to prevent or reduce disease</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>NVPEKQTRGIFGAIAGFIE</LinearSequence>
                                            <StartingPosition>322</StartingPosition>
                                            <EndingPosition>340</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P12589.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>119210</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>A/H3/HA0</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ComplexedMolecule>
                                        <ComplexType>Protein conjugate</ComplexType>
                                        <PeptideModifications/>
                                        <SourceMolecule>
                                            <GenBankId>AAA25457.1</GenBankId>
                                        </SourceMolecule>
                                        <MoleculeSourceOrganismId>487</MoleculeSourceOrganismId>
                                    </ComplexedMolecule>
                                </ImmunogenContainingObject>
                                <Adjuvant>Alum (Aluminum hydroxide gel)</Adjuvant>
                                <Adjuvant>QS21</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>2 doses, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>125</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Mice vaccinated with the epitope-OMPC conjugate were cross protected from infection with Influenza A/Puerto Rico/8/34 (H1N1), as measured by survival percentage and weight change.</AssayComments>
                        </AssayInformation>
                        <Antigen>
                            <AntigenReferenceName>Influenza A/Puerto Rico/8/34 (H1N1)</AntigenReferenceName>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>211044</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 7</LocationOfData>
                        <BCellId>1864300</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo to prevent or reduce disease</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>NVPEKQTRGIFGAIAGFIE</LinearSequence>
                                            <StartingPosition>322</StartingPosition>
                                            <EndingPosition>340</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P12589.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>119210</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>A/H3/HA0</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ComplexedMolecule>
                                        <ComplexType>Protein conjugate</ComplexType>
                                        <PeptideModifications/>
                                        <SourceMolecule>
                                            <GenBankId>AAA25457.1</GenBankId>
                                        </SourceMolecule>
                                        <MoleculeSourceOrganismId>487</MoleculeSourceOrganismId>
                                    </ComplexedMolecule>
                                </ImmunogenContainingObject>
                                <Adjuvant>Alum (Aluminum hydroxide gel)</Adjuvant>
                                <Adjuvant>QS21</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>2 doses, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>124</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Mice vaccinated with the epitope-OMPC conjugate were partially cross protected from infection with Influenza B/Ann Arbor/ 4/55.</AssayComments>
                        </AssayInformation>
                        <Antigen>
                            <AntigenReferenceName>Influenza B/Ann Arbor/ 4/55</AntigenReferenceName>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Taxonomic Child</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>10001880</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 8</LocationOfData>
                        <BCellId>15968</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Exposure with existing immune reactivity without evidence for disease</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11320</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>100</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>NVPEKQTRGIFGAIAGFIE</LinearSequence>
                                        <StartingPosition>322</StartingPosition>
                                        <EndingPosition>340</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P12589.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>119210</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 6</LocationOfData>
                        <BCellId>15962</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo to prevent or reduce disease</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>NVPEKQTRGIFGAIAGFIE</LinearSequence>
                                            <StartingPosition>322</StartingPosition>
                                            <EndingPosition>340</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P12589.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>119210</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>A/H3/HA0</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ComplexedMolecule>
                                        <ComplexType>Protein conjugate</ComplexType>
                                        <PeptideModifications/>
                                        <SourceMolecule>
                                            <GenBankId>AAA25457.1</GenBankId>
                                        </SourceMolecule>
                                        <MoleculeSourceOrganismId>487</MoleculeSourceOrganismId>
                                    </ComplexedMolecule>
                                </ImmunogenContainingObject>
                                <Adjuvant>Alum (Aluminum hydroxide gel)</Adjuvant>
                                <Adjuvant>QS21</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>2 doses, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>125</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Mice vaccinated with the epitope-OMPC conjugate were cross protected from infection with influenza A/H3 virus (Influenza A/Hong Kong/68XPR8) with 70% survival, compared to none in the control group, but suffered significant weight loss, albeit less severe than that of the controls.</AssayComments>
                        </AssayInformation>
                        <Antigen>
                            <AntigenReferenceName>Influenza A virus/Hong Kong/68XPR8</AntigenReferenceName>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>10000841</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>A/H1/HA0</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>NIPSIQSRGLFGAIAGFIE</LinearSequence>
                        <StartingPosition>337</StartingPosition>
                        <EndingPosition>355</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P18875.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>114727</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table 1</LocationOfData>
                <EpitopeId>44313</EpitopeId>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 8</LocationOfData>
                        <BCellId>15969</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Exposure with existing immune reactivity without evidence for disease</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11320</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>100</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>NIPSIQSRGLFGAIAGFIE</LinearSequence>
                                        <StartingPosition>337</StartingPosition>
                                        <EndingPosition>355</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P18875.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>114727</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

